Wegovy study details revive debate over GLP-1 impact on devices

Shares in several heart device makers, which have been battered over the perceived impact of obesity medicines, rose this week following AHA data on Novo’s therapy.

By Susan Kelly • Nov. 13, 2023

Biogen, Sage set price of postpartum depression pill at $15,900

The price is below what some analysts had predicted and significantly less than $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.

By Ned Pagliarulo • Nov. 7, 2023

Explore the Trendline➔

Pharma, new drugs and market strategy

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Transforming MS care to meet patient needs

Developing holistic treatment approaches that address patient needs today and in the future.

By Abhijit Barve, MD, PhD, MBA, Chief Medical Officer, Viatris • Nov. 6, 2023

Novo, Lilly buoyed by fast-growing GLP-1 drug sales

The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

By Jonathan Gardner • Nov. 2, 2023

The obesity drug effect: What medical device executives are saying

Stock selloffs across the medical device sector have erased hundreds of billions of dollars in market value. But medtech executives argue GLP-1 drug demand will complement, not cannibalize, their sales. 

By Susan Kelly • Nov. 2, 2023

GSK outpaces Pfizer in RSV vaccine market

Sales of GSK’s new RSV shot Arexvy were more than double what Pfizer reported for its rival product, suggesting substantial demand this fall.

By Kristin Jensen • Nov. 1, 2023

5 things to look for in a marketing analytics partner

Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.

Oct. 23, 2023

Roche eye drug sales grow as Regeneron plays catch-up

The Swiss pharma reported expanding U.S. market share for its new AMD drug Vabysmo as Regeneron tries to rebound from a now-resolved delay for its high-dose Eylea.

By Jonathan Gardner • Oct. 19, 2023

Keytruda gains first approval for pre- and post-surgery use in lung cancer

The Merck drug leads competitors Opdivo and Imfinzi into a new immunotherapy setting, which aims to improve outcomes following the surgical removal of tumors.

By Jonathan Gardner • Oct. 17, 2023

Pfizer wins FDA approval for its $7B colitis drug

Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.

By Jonathan Gardner • Oct. 13, 2023

Amylyx’s ALS drug knocked back again in Europe

Following a re-examination, the EMA again concluded that Albrioza — known as Relyvrio in the U.S. — should not be cleared for the European market.

By Jacob Bell • Oct. 13, 2023

GLP-1 drug demand leaves employers in a bind over coverage

Employers face a difficult decision over whether to cover the popular weight loss therapies, which cost between $900 and $1,400 for a typical month’s supply at list price.

By Rebecca Pifer • Oct. 13, 2023

Apellis sales numbers show steady demand for new eye drug, despite safety worries

The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.

By Kristin Jensen • Oct. 5, 2023

Using AI to create an end-to-end customer experience in pharma

Silos abound in the pharma world, especially when it comes to customer care and call center support. Using AI can change everything, though. Here’s how.

Oct. 2, 2023

Eisai’s Alzheimer’s drug Leqembi approved in Japan

Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.

By Ned Pagliarulo • Sept. 25, 2023

New RSV vaccines can be powerful tools, but rollout poses test

Public health officials, as well as drugmakers, are trying to raise awareness of RSV among older adults at risk, and convince them to get an additional respiratory shot alongside those for COVID-19 and flu.

By Delilah Alvarado • Sept. 18, 2023

FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet

The drug, known scientifically as momelotinib, is now cleared to treat myelofibrosis and will compete against rival medicines sold by Incyte and Bristol Myers Squibb.

By Jacob Bell • Sept. 18, 2023

J&J to phase out Janssen name in corporate rebrand

Janssen will be recast as Johnson & Johnson Innovative Medicine, melding the drugs division’s identity more closely with its parent.

By Ned Pagliarulo • Sept. 15, 2023

Insulin pump-makers grapple with questions about GLP-1s

New weight loss drugs have sparked a stock selloff for some device makers, but medtech analysts don’t see them a likely to undermine the companies’ business — yet. 

By Elise Reuter • Sept. 14, 2023

Akili cuts 40% of workforce, plans shift to non-prescription model

The digital therapeutics company expects to extend its cash runway into 2025 with the changes.

By Elise Reuter • Sept. 13, 2023

CDC endorses new COVID boosters as focus turns to rollout

This fall will now feature vaccination campaigns for COVID-19, influenza and respiratory syncytial virus.

By Delilah Alvarado • Sept. 13, 2023

Do not miss the return to growth

The signals of a return to growth are emerging. As commercial leaders gear up for 2024 planning, they must prepare to fight for resources in a budget constrained environment.

By Alexander Group • Sept. 5, 2023

FTC allows Amgen’s $28B deal for Horizon to go through, with conditions

The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.

By Jonathan Gardner • Sept. 1, 2023

FTC pulls back on legal challenge to Amgen’s $28B bid for Horizon

Urged by a judge, the antitrust regulator said it wants to start discussions “regarding the proper resolution of this matter” — a potential prelude to a settlement.

By Jonathan Gardner • Aug. 28, 2023

AstraZeneca the latest pharma to challenge drug pricing law

The drugmaker's lawsuit follows similar legal challenges from Merck & Co., Bristol Myers Squibb and Johnson & Johnson, among others. 

By Ned Pagliarulo • Aug. 25, 2023